Nanotechnology Now - Press Release: Azaya Therapeutics, Inc. Elects Ze’ev Shaked, Ph.D., to Board of Directors

Home > Press > Azaya Therapeutics, Inc. Elects Ze’ev Shaked, Ph.D., to Board of Directors

Abstract:
Brings Track Record of Successful Product Commercialization

Azaya Therapeutics, Inc. Elects Ze’ev Shaked, Ph.D., to Board of Directors

SAN ANTONIO, TX | Posted on May 31st, 2007

Azaya Therapeutics, Inc. today announced the election of Dr. Ze'ev Shaked to its Board of Directors. Dr. Shaked has extensive managerial and pharmaceutical product development experience in commercializing new drug products. He most recently was President and CEO of Spherics, Inc., where he transformed the company into a product-driven company with an attractive product pipeline, and where he raised more than $25 million from the venture capital industry.

Prior to Spherics, Dr. Shaked was Chief Operating Officer of ILEX Oncology, Inc., in San Antonio, Texas. He was instrumental in ILEX obtaining ownership and FDA approval for CAMPATH and Clolar, two of its commercialized products. In addition, Dr. Shaked has held a number of senior research and development and corporate management positions at ImmuLogic Pharmaceutical Corporation, Berlex Biosciences, Inc., Triton Biosciences, Inc., CODON Corporation, and Chiron Corporation. He obtained his Ph.D. in Organic Chemistry and Applied Biochemistry from the Massachusetts Institute of Technology.

"Ze'ev Shaked has an outstanding track record in the biopharmaceutical industry and in overseeing the development of new drugs," said John Kerr, chairman of the board of Azaya. "His wealth of scientific experience will be invaluable in guiding the overall development of Azaya's pipeline of products."

####

About Azaya Therapeutics, Inc.
Azaya Therapeutics, Inc., is an emerging nanotherapy company with an innovative technology platform – Protein Stabilized Nanoparticles – (PSNTM) designed to significantly improve the efficacy and safety of water insoluble pharmaceutical agents. Azaya is initially building an in-house pipeline of safer and more efficacious nanoparticle chemotherapy drug products. Azaya was granted a patent on this technology in February 2007.

For more information, please click here

Contacts:
Azaya Therapeutics, San Antonio
Michael T. Dwyer, 210-341-6600
or
Dublin & Associates
Eric Whittington, 210-227-0221, ext. 239

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: